Literature DB >> 14684453

Clinical studies implementing glutamate neurotransmission in mood disorders.

Gerard Sanacora1, Douglas L Rothman, Graeme Mason, John H Krystal.   

Abstract

Emerging evidence suggests that the amino acid neurotransmitter systems are associated with the pathophysiology and treatment of mood disorders. Recent advances in the areas of molecular neurobiology, pharmacology, and magnetic resonance spectroscopy (MRS) now provide better tools to probe the function of the amino acid neurotransmitter systems and are affording us the opportunity to better investigate the relationship of these systems to mood disorders. Here we review the available literature in the field and suggest a possible pathophysiological model that may account for the many of the findings.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14684453     DOI: 10.1196/annals.1300.018

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  49 in total

1.  Glia mechanisms in mood regulation: a novel model of mood disorders.

Authors:  Younglim Lee; Denise Gaskins; Amit Anand; Anantha Shekhar
Journal:  Psychopharmacology (Berl)       Date:  2007-01-16       Impact factor: 4.530

2.  Enhancing AMPA to NMDA throughput as a convergent mechanism for antidepressant action.

Authors:  Jing Du; Rodrigo Machado-Vieira; Sungho Maeng; Keri Martinowich; Husseini K Manji; Carlos A Zarate
Journal:  Drug Discov Today Ther Strateg       Date:  2006

3.  Glutamine deficiency in the prefrontal cortex increases depressive-like behaviours in male mice.

Authors:  Younghyurk Lee; Hyeonwi Son; Gyeongwha Kim; Sujeong Kim; Dong Hoon Lee; Gu Seob Roh; Sang Soo Kang; Gyeong Jae Cho; Wan Sung Choi; Hyun Joon Kim
Journal:  J Psychiatry Neurosci       Date:  2013-05       Impact factor: 6.186

4.  Lower glutamate levels in rostral anterior cingulate of chronic cocaine users - A (1)H-MRS study using TE-averaged PRESS at 3 T with an optimized quantification strategy.

Authors:  Shaolin Yang; Betty Jo Salmeron; Thomas J Ross; Zheng-Xiong Xi; Elliot A Stein; Yihong Yang
Journal:  Psychiatry Res       Date:  2009-11-10       Impact factor: 3.222

5.  Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist.

Authors:  Laura E Phelps; Nancy Brutsche; Jazmin R Moral; David A Luckenbaugh; Husseini K Manji; Carlos A Zarate
Journal:  Biol Psychiatry       Date:  2008-11-08       Impact factor: 13.382

6.  Rapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with riluzole.

Authors:  Brian P Brennan; James I Hudson; J Eric Jensen; Julie McCarthy; Jacqueline L Roberts; Andrew P Prescot; Bruce M Cohen; Harrison G Pope; Perry F Renshaw; Dost Ongür
Journal:  Neuropsychopharmacology       Date:  2009-12-02       Impact factor: 7.853

7.  Amino acid neurotransmitters assessed by proton magnetic resonance spectroscopy: relationship to treatment resistance in major depressive disorder.

Authors:  Rebecca B Price; Dikoma C Shungu; Xiangling Mao; Paul Nestadt; Chris Kelly; Katherine A Collins; James W Murrough; Dennis S Charney; Sanjay J Mathew
Journal:  Biol Psychiatry       Date:  2008-12-05       Impact factor: 13.382

8.  Altered expression of glutamate signaling, growth factor, and glia genes in the locus coeruleus of patients with major depression.

Authors:  R Bernard; I A Kerman; R C Thompson; E G Jones; W E Bunney; J D Barchas; A F Schatzberg; R M Myers; H Akil; S J Watson
Journal:  Mol Psychiatry       Date:  2010-04-13       Impact factor: 15.992

9.  Reduced expression of GABA transporter GAT3 in helpless rats, an animal model of depression.

Authors:  M Zink; B Vollmayr; P J Gebicke-Haerter; F A Henn
Journal:  Neurochem Res       Date:  2009-03-15       Impact factor: 3.996

Review 10.  The neurobiological properties of tianeptine (Stablon): from monoamine hypothesis to glutamatergic modulation.

Authors:  B S McEwen; S Chattarji; D M Diamond; T M Jay; L P Reagan; P Svenningsson; E Fuchs
Journal:  Mol Psychiatry       Date:  2009-08-25       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.